Syncom Formulations Q2 FY26: H1 revenue up 27%, PAT jumps 75%

Revenue growth above 20%Profit growth above 25%EBITDA margin expansionExceptional itemResults View source PDF Explain this filing

SYNCOMF · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.4%Reaction day

₹16.36

prior close

₹16.84

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%+2.5% vs market

Pharmaceuticals peers, median of 157sector-0.1%+2.6% vs sector

On the reaction day the stock moved 2.5 pts more than Nifty Microcap 250 and 2.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.4

10m

+1.9

15m

+0.2

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.4-0.1+2.5-0.1+2.6

Next day

+1.7-0.2+1.9-0.5+2.2

+1.7+0.4+1.3-0.4+2.1

+0.5-0.4+0.9-1.1+1.6

-1.3-0.6-0.7-1.4+0.1

-1.6-0.9-0.7-1.5-0.1

-5.7-3.0-2.7-3.2-2.6

15d

-5.9-3.9-2.1-3.4-2.5

-8.3-4.8-3.4-4.0-4.2

-20.3-7.8-12.5-6.6-13.7

-14.9-7.2-7.7-8.5-6.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Syncom Formulations posted strong H1 FY26 results. Standalone revenue rose 27% to Rs 23,798 lakhs, while PAT surged 75% to Rs 3,257 lakhs. Q2 standalone revenue grew about 20% YoY to Rs 12,144 lakhs with PAT up 54% to Rs 1,684 lakhs. PBT margin expanded from around 13% to 17% YoY. Operating cashflow stayed positive at Rs 5,568 lakhs. Statutory auditor issued an unqualified limited review report for both standalone and consolidated results.

Likely market impact

Strong double-digit revenue and profit growth with margin expansion signals healthy momentum and supports investor sentiment positively.